Decreasing disease severity in symptomatic, Smn-/-;SMN2 ++, spinal muscular atrophy mice following scAAV9-SMN delivery

Human Gene Therapy

Volumn 23, Issue 3, 2012, Pages 330-335

  Glascock, Jacqueline J ^a,b   Osman, Erkan Y ^a,b   Wetz, Mary J ^a,b   Krogman, Megan M ^a,b   Shababi, Monir ^a,b   Lorson, Christian L ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; SURVIVAL MOTOR NEURON PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; GENE REPLACEMENT THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; SPINAL MUSCULAR ATROPHY; SURVIVAL;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; MICE; MICE, TRANSGENIC; MUSCULAR ATROPHY, SPINAL; SEVERITY OF ILLNESS INDEX; SMN COMPLEX PROTEINS;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

EID: 84858026947     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.166     Document Type: Article

References (22)

1. Avila, A.M., Burnett, B.G., Taye, A.A., et al. (2007). Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117, 659-671. (Pubitemid 46348524)
2. Baughan, T.D., Dickson, A., Osman, E.Y., et al. (2009). Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum. Mol. Genet. 18, 1600-1611.
3. Bish, L.T., Morine, K., Sleeper, M.M., et al. (2008). Adenoassociated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359-1368.
4. Burghes, A.H., and McGovern, V.L. (2010). Antisense oligonucleotides and spinal muscular atrophy: skipping along. Genes Dev. 24, 1574-1579.
5. Coady, T.H., and Lorson, C.L. (2010). Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. J. Neurosci. 30, 126-130.
6. Dominguez, E., Marais, T., Chatauret, N., et al. (2011). Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 20, 681-693.
7. Duque, S., Joussemet, B., Riviere, C., et al. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17, 1187-1196.
8. Foust, K.D., Nurre, E., Montgomery, C.L., et al. (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65.
9. Foust, K.D., Wang, X., McGovern, V.L., et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271-274.
10. Grieger, J.C., Choi, V.W., and Samulski, R.J. (2006). Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1, 1412-1428.
11. Inagaki, K., Fuess, S., Storm, T.A., et al. (2006). Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45-53. (Pubitemid 43899488)
12. Le, T.T., Pham, L.T., Butchbach, M.E., et al. (2005). SMND7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845-857. (Pubitemid 40403280)
13. Lefebvre, S., Burglen, L., Reboullet, S., et al. (1995). Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155-165.
14. Lutz, C.M., Kariya, S., Patruni, S., et al. (2011). Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J. Clin. Invest. 121, 3029-3041.
15. Mattis, V.B., Rai, R., Wang, J., et al. (2006). Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum. Genet. 120, 589-601. (Pubitemid 44669792)
16. Monani, U.R., Sendtner, M., Coovert, D.D., et al. (2000). The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-/-mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333-339. (Pubitemid 30098725)
17. Passini, M.A., Bu, J., Roskelley, E.M., et al. (2010). CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest. 120, 1253-1264.
18. Shababi, M., Mattis, V.B., and Lorson, C.L. (2010a). Therapeutics that directly increase SMN expression to treat spinal muscular atrophy. Drug News Perspect. 23, 475-482.
19. Shababi, M., Habibi, J., Yang, H.T., et al. (2010b). Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum. Mol. Genet. 19, 4059-4071.
20. Shababi, M., Glascock, J., and Lorson, C.L. (2011). Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Hum. Gene Ther. 22, 135-144.
21. Valori, C.F., Ning, K., Wyles, M., et al. (2010). Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2, 35ra42.
22. Wishart, T.M., Huang, J.P., Murray, L.M., et al. (2010). SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum. Mol. Genet. 19, 4216-4228.